Sun Pharmaceutical Industries Limited has entered into an agreement with HaystackAnalytics Private Limited ("Haystack"), pursuant to which Sun Pharma has agreed to acquire 9.6% of total outstanding securities.

HaystackAnalytics is engaged in the business of developing genomic analysis software that enables clinical decision-making through culturefree, comprehensive, and fast clinical genomics by automating bioinformatic analysis to produce clear and clinically relevant reports and utilization of the genomic data and their analysis for creation of new products for healthcare.